PDF factsheet

antithrombotics in acute myocardial infarction for all type of patients, clinical trials results

any anticoagulant versus aspirin
EPSIM, 1982	anticoagulant versus aspirin 500mg three times daily	patients surviving myocardial infarction	open Follow-up duration: 29 months (range 6-59)
any anticoagulant versus placebo
Sixty Plus reinfarction Study, 1980	anticoagulant versus placebo	over 60 years of age	double blind Follow-up duration: 2 years
Argatroban versus heparin
ARGAMI-2, 1998	Argatroban 60–20 mg/kg bolus; 2–4 µg /kg/min infusion for 72h versus UFH 5000 IU bolus; 1000 IU/h infusion	AMI	Follow-up duration: 30 days
bivalirudin versus heparin
HERO, 1997	Bivalirudin 0.125–0.250 mg/kg bolus; 0.125–0.500 mg /kg/min infusion for 72h versus UFH 5000 IU bolus; 1000–1200 IU/h infusion	AMI (patients presenting within 12 hours with ST-segment elevation)	double blind Follow-up duration: 35 days
coumadin versus aspirin
ASPECT-2 (coumadin alone), 2002	coumadin (phenprocoumon or acenocoumarol) target INR 3-4 versus aspirin 80mg daily	Acute MI, unstable angina	open Follow-up duration: 1 year (range 0-26 months) the Netherlands
coumadin versus control (on top of aspirin)
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin(INR mean 2.4) +aspirin versus aspirin	Acute MI, unstable angina	open Follow-up duration: 1 year the Netherlands
coumadin versus placebo
ASPECT, 1994	nicoumalone or phenprocoumon, target INR 2.8–4.8 versus placebo	hospital survivors of myocardial infarction	double blind Follow-up duration: 37 months (range 6-76)
Dalteparin versus placebo
BIOMACS II, 1999	Dalteparin 100 mg/kg, 2 doses versus placebo	patients with acute myocardial infarction, Age <=80 y, STEMI or new LBBB	Double-blind Follow-up duration: 14–21 d
FRAMI, 1997	Dalteparin 150 mg/kg BID for 7–11 d versus placebo	patients with an acute MI, Q wave or STEMI	Double-blind Follow-up duration: in hospital
Dalteparin versus UFH
ASSENT Plus, 2003	Dalteparin first dose 90 IU/kg, then 120 IU/kg BID, 4–7 d versus UFH 4000–5000 IU bolus, then 800–1000 IU/h for 48 h	Patients with AMI treated with alteplase	open Follow-up duration: 30 d
Enoxaparin versus placebo
AMI-SK, 2002	Enoxaparin 30 mg IV bolus, 1 mg/kg for 3–8 d versus placebo	patients with evolving myocardial infarction, Age >=18 y, STEMI	Double-blind Follow-up duration: 30 d
Enoxaparin versus UFH
ASSENT 3 Plus, 2003	Enoxaparin 1 mg/kg BID, <=7d versus UFH 60 IU/kg, then 12 IU/kg per h for >=3d	patients with ST-elevation myocardial infarction	open Follow-up duration: 30 d
ASSENT 3, 2001	Enoxaparin 1 mg/kg BID, <=7d versus UFH 60 U/kg bolus, then 12 IU/kg per h for 48 h	patients with acute myocardial infarction	open Follow-up duration: 30 d
Baird, 2002	Enoxaparin 40 mg TID, 4 d versus UFH 5000 IU bolus, then 30 000 IU over 24 h for 4d	patients receiving fibrinolytic therapy following acute myocardial infarction	90-min TIMI flow Follow-up duration: 90 d
ENTIRE-TIMI 2, 2002	Enoxaparin 1 mg/kg BID, <=8d versus UFH 60 IU/kg, then 12 IU/kg per h for >=3d	Patients with ST-elevation MI presenting <6 hours from symptom onset were	open Follow-up duration: 30 d
HART II, 2001	Enoxaparin 1 mg/kg BID, <=3d versus UFH 4000–5000 IU bolus, then 15 IU/kg per hour for >=3d	patients undergoing reperfusion therapy with an accelerated recombinant tissue plasminogen activator regimen and aspirin for AMI	open Follow-up duration: 5–7 d
fondaparinux versus placebo
MICHELANGELO OASIS-6, 2006 NCT00064428	fondaparinux 2.5 mg once daily up to 8 days versus control (UFH or placebo)	patients with STEMI	double-blind Follow-up duration: 30 days 41 countries
Hirudin versus heparin
HIT-4, 1999	Hirudin 0.2 mg/kg bolus; 0.5 mg/kg twice daily 0.1 mg/kg 0.1 mg /kg/h infusion for 5-7 days versus Placebo bolus, UFH 12 500 IU twice daily	patients with AMI <=6 h were treated with aspirin and streptokinase	double blind Follow-up duration: 30 days
TIMI 9B, 1996	Hirudin 0.1 mg/kg bolus; 0.1 mg /kg/h infusion for 96h versus UFH 5000 IU bolus; 1000 IU/h infusion	Unstable angina or AMI	open Follow-up duration: 30 days
phenprocoumon versus aspirin
German-Austrian Study Group (oac vs asp), 1980	phenprocoumon versus aspirin 1.5 g daily	patients who had survived a myocardial infarction for 30-42 days	double blind Follow-up duration: 2 years
phenprocoumon versus placebo
German-Austrian Study Group (oac vs pbo), 1980	phenprocoumon versus placebo	patients who had survived a myocardial infarction for 30-42 days	double blind Follow-up duration: 2 years
Reviparin versus placebo
CREATE, 2005	Reviparin 3436–6871 IU BID for 7 d (weight adjusted) versus placebo	patients with acute myocardial infarction, STEMI or new LBBB, <=12 h	Double-blind Follow-up duration: 30 d
UFH versus no heparin
ISIS-2 Pilot, 1987	UFH nNo bolus, 1000 IU/h for 48 h versus No heparin	patients with suspected MI <=24 h	open Follow-up duration: In-hospital, 1 y (deat
DUCCS, 1994	UFH no bolus, 15 IU/kg per h for 4 d; target aPTT 50–90 s versus No heparin	patients with acute myocardial infarction four hours after APSAC administration, age <=85 y STEMI <=12 h	open Follow-up duration: 14 d
UFH versus placebo
ECSG, 1992	UFH 5000 IU bolus, UFH 1000 IU/h for 48–120 h versus Placebo	patients treated with alteplase thrombolysis for acute myocardial infarction, Age 21–70 y STEMI <=6h	Double-blind Follow-up duration: In-hospital
OSIRIS, 1992	UFH 10 000 IU bolus, 1000 IU/h for 24 h versus Placebo	STEMI w=6 h	Double-blind Follow-up duration: In-hospital
warfarin versus aspirin
WARIS II (warfarin alone), 2002	warfarin target INR 2.8-4.2 versus ASA 160mg/d	patients hospitalized for acute myocardial infarction	NA Follow-up duration: 48 months Norway
warfarin versus control (on top of aspirin)
WARIS, 1999	warfarin 2.8–4.8 versus placebo	survivors of acute myocardial infarction	double blind Follow-up duration: 37 months
APRICOT-2, 2002	moderate-intensity coumarin target INR 2-3 (+aspirin) versus aspirin	Acute MI after thrombolytics	open Follow-up duration: 3 months the Netherlands
CARS (warafrin 3mg), 1997	warfarin fixed dose 3mg/d + 80 mg ASA versus aspirin 160 mg/d	AMI	double blind Follow-up duration: 14 months North America
CARS (warfarin 1mg), 1997	warfarin 1mg/d + aspirin 80mg/d versus aspirin 160 mg/d	patients who had had myocardial infarction	double blind Follow-up duration: 14 months North America
CHAMP, 2002	warfarin target INR 1.5-2.5 + aspirin 81 mg daily versus aspirin 162 mg/d	AMI (patients enrolled within 14 days of infarction)	open Follow-up duration: 2.7 years US
LoWASA, 2004	warfarin fixed dose 1.25mg/d + ASA 75mg/d versus aspirin alone	AMI	open Follow-up duration: 5 years Sweden
WARIS II (warfarin+ASA), 2002	warfarin target INR 2-2.5 +ASA 75mg/d versus ASA 160mg/d	patients hospitalized for acute myocardial infarction	open Follow-up duration: 4 years Norway
Zibaeenezhad, 2004	Warfarin target INR 2–3 +aspirin versus aspirin 100 mg/day	Acute MI	open Follow-up duration: 1 year
warfarin versus placebo (on top of aspirin)
Williams, 1997	warfarin target INR 2–2.5 +aspirin versus placebo +aspirin	Acute MI, unstable angina	double blind Follow-up duration: 2.5 months

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags